Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for ETX101 in SCN1A+ Dravet Syndrome Yahoo Finance Nawigacja wpisu Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? – Yahoo Finance Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome – Biogen
